News in the Life Sciences Industry

HSINCHU, Taiwan, March 8, 2019 /PRNewswire/ -- TaiwanJ Pharmaceuticals has signed a US$26 million contract with Newsoara Biopharma to license out its drug candidate JKB-122 for further development in Asia. On March 2(nd), 2019, TaiwanJ announced that its JKB-122, an effective phase 2 nonalcoholic... Read more ››

TAIPEI, Taiwan and TOKYO, March 5, 2019 /PRNewswire/ -- Health2Sync and Novo Nordisk Pharma Ltd. are partnering in Japan to support digital diabetes management and facilitate communication between diabetics and healthcare providers. Last December, the two companies agreed to support the localization... Read more ››

BURLINGTON, Mass., Feb. 21, 2019 /PRNewswire/ -- PharmaEssentia today announced that the European Commission (EC) has approved Besremi(®) (ropeginterferon alfa-2b, P1101) as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly. The European market authorization... Read more ››

TAIPEI, Taiwan, February 21, 2019 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today the topline results of FP-001 LMIS (Leuprolide Mesylate Injectable Suspension) 25 mg phase 3 clinical trial, an open-label, single-arm study in subjects with Prostate Carcinoma.... Read more ››

GYEONGGI, South Korea, Feb. 14, 2019 /PRNewswire/ -- SK Biopharmaceuticals and Arvelle Therapeutics GmbH today announced that they have entered into an exclusive licensing agreement for Arvelle to develop and commercialize cenobamate in Europe. Cenobamate is a novel, small molecule investigational... Read more ››

TAIPEI, Taiwan, Feb. 14, 2019 /PRNewswire/ -- A team led by Dr. Chi-Huey Wong, Distinguished Research Fellow, Academia Sinica in Taiwan, in collaboration with OBI scientists, has demonstrated in a recent study that the Globo-series glycosphingolipid (GSL) antigens: Globo-H, SSEA-3, and SSEA-4... Read more ››